Industry News (Biotechnology)

Chemical Entities/Vaccines To Be Filed Over Next Three Years

Published in Hepatitis Weekly, October 9th, 1995

Over the next three years, SmithKline Beecham (SB) said it expects to seek more than 50 regulatory approvals for its pharmaceutical products, including submissions for 13 new chemical entities, 8 new vaccines, 12 new combination vaccines and 26 supplemental registrations for new uses and dosing methods for marketed products.

"Our product pipeline is strong and extremely promising," R&D Chairman George Poste told a group of financial analysts at SB's Research and Development [R&D] Review Meeting. "It has the scale, balance and quality to put SmithKline Beecham at the top of our industry."

Poste and top SB R&D executives reviewed the company's...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Hepatitis Weekly

Source: Hepatitis Weekly (1995-10-09)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry